Endothelial Function in Patients with Hyperthyroidism Before and After Treatment with Propranolol and Thiamazol
- 1 February 2001
- journal article
- research article
- Published by Mary Ann Liebert Inc in Thyroid®
- Vol. 11 (2) , 153-160
- https://doi.org/10.1089/105072501300042820
Abstract
Hyperthyroidism is associated with a higher incidence of arterial thromboembolism; increasing age, atrial fibrillation, and mitral valve abnormalities are risk factors. However, the contribution of endogenous coagulation parameters is unclear. Because thyroid hormone influences receptor and transcription factors, it can be expected that it will influence proteins involved in coagulation processes synthetised in many cells. Fourteen hyperthyroid patients were studied untreated, after 1 week of treatment with propranolol, and after therapeutic treatment with thiamazol. Fourteen matched controls were used for comparison. On each occasion, endothelial marker proteins, coagulation/fibrinolysis factors, and inflammatory (liver) markers were measured. Excess thyroid hormone was associated with elevated levels of most endothelium-associated proteins. In addition, plasma fibronectin and fibrinogen were increased, while plasminogen was decreased. No evidence was found that hyperthyroidism was associated with coagulation/fibrinolysis activation, or with increased levels of the inflammation markers interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) or C-reactive protein (CRP). Propranolol treatment only lowered the von Willebrand factor propeptide, and slightly increased plasminogen. Treatment with thiamazol returned all parameters to normal. Hyperthyroidism increased the plasma levels of most endothelial marker proteins, and of some liver-synthetized proteins. No evidence for coagulation/fibrinolysis activation was found. However, it appears that endothelial activation, which is indicative of a procoagulant state, is present in hyperthyroidism. This may explain the association between hyperthyroidism and thromboembolism especially if other risk factors are present. von Willebrand factor II (vWF:Ag-II) levels may be suitable markers to evaluate acute changes in endothelial function because this parameter responds more rapidly to changes in endothelial function than other factors.Keywords
This publication has 40 references indexed in Scilit:
- Power spectral analysis of heart rate in hyperthyroidismJournal of Clinical Endocrinology & Metabolism, 1996
- Behavior of soluble intercellular adhesion molecule-1 and endothelial- leukocyte adhesion molecule-1 concentrations in patients with Graves' disease with or without ophthalmopathy and in patients with toxic adenomaJournal of Clinical Endocrinology & Metabolism, 1995
- Experimental hypothyroidism increases plasminogen activator inhibitor activity in rat plasmaBlood Coagulation & Fibrinolysis, 1993
- Relationship of thyroid states and serum thrombomodulin (TM) levels in patients with Graves' disease: TM, a possible new marker of the peripheral activity of thyroid hormonesJournal of Clinical Endocrinology & Metabolism, 1993
- Activation of Blood Coagulation and Fibrinolysis in Graves' DiseaseHormone and Metabolic Research, 1991
- A sensitive ELISA for von Willebrand factor (vWf:Ag)Scandinavian Journal of Clinical and Laboratory Investigation, 1987
- Changes in Plasma Fibronectin Levels in Thyroid DiseasesHormone and Metabolic Research, 1986
- Arterial embolism in thyrotoxicosis with atrial fibrillationArchives of internal medicine (1960), 1981
- Coagulation and Fibrinolysis in Thyroid DiseaseActa Haematologica, 1978
- Hyperthyroidism as a high cardiac output stateAmerican Heart Journal, 1970